Stockscreener 앱 받기
0.9801
2.96%
-0.0299
Werewolf Therapeutics Inc 주식(HOWL)의 최신 뉴스
Cocrystal Pharma, Inc. (COCP) Stock Price & News - Syfe
AEON Biopharma, Inc. (AEON) Stock Price & News - Syfe
QNRX Stock Price, Quote & News - Syfe
Theriva Biologics, Inc. (TOVX) Stock Price & News - Syfe
Werewolf Therapeutics, Inc. (HOWL) Stock Price, News, Quote & History - Yahoo! Finance Canada
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome - Zacks Investment Research
Lite Strategy, Inc. (LITS) Stock Price & News - Syfe
Valion Bio, Inc. (VBIO) Stock Price & News - Syfe
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why - Zacks Investment Research
TGTX Stock Rises 60% in 6 Months: Here's What You Should Know - Zacks Investment Research
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases - Zacks Investment Research
New Strong Buy Stocks for October 9th - Zacks Investment Research
Marker Therapeutics, Inc. (MRKR) Stock Price & News - Syfe
Scienture Holdings, Inc. (SCNX) Stock Price & News - Syfe
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. ( - mykxlg.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. ( - True North Radio Network
Kairos Pharma, Ltd. (KAPA) Stock Price & News - Syfe
Ambros deal would give Werewolf (NASDAQ: HOWL) investors rights to future sales of legacy drug assets - Stock Titan
German investor discloses stake in Werewolf Therapeutics (NASDAQ: HOWL) - Stock Titan
Werewolf Therapeutics (HOWL) Dips 1.43% to $0.97 as Tight Trading Range Sends Stock Toward Key SupportEarnings Miss Risk - dars.gov.et
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
CalciMedica, Inc. (CALC) Stock Price & News - Syfe
Werewolf Therapeutics Stock Price Forecast. Should You Buy HOWL? - StockInvest.us
Werewolf Therapeutics stock gains on merger scrutiny and trial progress - ad-hoc-news.de
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Lantern Pharma Inc. (LTRN) Stock Price & News - Syfe
Actuate Therapeutics, Inc. (ACTU) Stock Price & News - Syfe
Onconetix, Inc. (ONCO) Stock Price & News - syfe.com
BioXcel Therapeutics, Inc. (BTAI) Stock Price & News - Syfe
Valion Bio, Inc. (VBIO) Stock Price & News - Syfe
Werewolf Therapeutics Completes Key Early Trial For WTX-124 In Hard-To-Treat Cancers - TipRanks
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the MergerHOWL, HZO, TYFG and FULC - Sahm
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Werewolf, Ambros to Merge in All-Stock Deal - Contract Pharma
HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - The Daily Tribune News
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the MergerHOWL, HZO, TYFG and FULC - PR Newswire
Werewolf Therapeutics And Ambros Therapeutics Merge With $150 Million PIPE To Advance Phase III CRPS Drug Neridronate - Pulse 2.0
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the MergerHOWL, HZO, TYFG and FULC - Morningstar
Werewolf (HOWL) Outlook: Moves 102.57% Up to $0.87 in the Latest Reading; Boundary Watch: $0.83 and $0.91 Define the Nearby Reference Levels at the CloseMoving Average Ribbon - vinanet.vn
Werewolf (HOWL) Outlook: Moves 102.57% Up to $0.87 in the Latest Reading; Boundary Watch: $0.83 and $0.91 Define the Nearby Reference Levels at the CloseMESA MA - siam.in
HOWL | Werewolf Therapeutics, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Ambros Therapeutics to merge with Werewolf Therapeutics in all-stock deal - Dealroom
Werewolf Therapeutics (NASDAQ:HOWL) Deal Changes Pipeline Focus - Kalkine Media
Werewolf Therapeutics Shares Surge Twofold After Ambros Merger, Investors Retain 6.8% Stake - TechStock²
Latham Watkins Advises on Oversubscribed Private Placement in Werewolf Ambros Merger Transaction - Latham & Watkins LLP
Werewolf Therapeutics, Inc. announced that it expects to receive $150 million in funding - marketscreener.com
Werewolf Therapeutics Strikes Reverse Merger With Ambros, Secures $150 Million for Rare Pain Drug - finance.biggo.com
Trending Stocks Today | Werewolf Therapeutics Shoots up 117.27% - Moomoo
Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News - Yahoo Finance
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
3.09%
0.72%
자본화:
|
볼륨(24시간):